Abstract
Survivors of severe brain injuries may end up in a state of ‘wakeful unresponsiveness’ or in a minimally conscious state. Pharmacological treatments of patients with disorders of consciousness aim to improve arousal levels and recovery of consciousness. We here provide a systematic overview of the therapeutic effects of amantadine, apomorphine and zolpidem in patients recovering from coma. Evidence from clinical trials using these commonly prescribed pharmacological agents suggests positive changes of the patients’ neurological status, leading sometimes to dramatic improvements. These findings are discussed in the context of current hypotheses of these agents’ therapeutic mechanisms on cerebral function. In order to improve our understanding of the underlying pathophysiological mechanisms of these drugs, we suggest combining sensitive and specific behavioral tools with neuroimaging and electrophysiological measures in large randomized, double-blind, placebo-controlled experimental designs. We conclude that the pharmacokinetics and pharmacodynamics of amantadine, apomorphine and zolpidem need further exploration to determine which treatment would provide a better neurological outcome regarding the patient’s etiology, diagnosis, time since injury and overall condition.
Keywords: Amantadine, apomorphine, zolpidem, disorders of consciousness, vegetative state/unresponsive wakefulness syndrom, minimally conscious state, pharmacological treatments, mechanism of action.
Current Pharmaceutical Design
Title:Amantadine, Apomorphine and Zolpidem in the Treatment of Disorders of Consciousness
Volume: 20 Issue: 26
Author(s): Olivia Gosseries, Vanessa Charland-Verville, Marie Thonnard, Olivier Bodart, Steven Laureys and Athena Demertzi
Affiliation:
Keywords: Amantadine, apomorphine, zolpidem, disorders of consciousness, vegetative state/unresponsive wakefulness syndrom, minimally conscious state, pharmacological treatments, mechanism of action.
Abstract: Survivors of severe brain injuries may end up in a state of ‘wakeful unresponsiveness’ or in a minimally conscious state. Pharmacological treatments of patients with disorders of consciousness aim to improve arousal levels and recovery of consciousness. We here provide a systematic overview of the therapeutic effects of amantadine, apomorphine and zolpidem in patients recovering from coma. Evidence from clinical trials using these commonly prescribed pharmacological agents suggests positive changes of the patients’ neurological status, leading sometimes to dramatic improvements. These findings are discussed in the context of current hypotheses of these agents’ therapeutic mechanisms on cerebral function. In order to improve our understanding of the underlying pathophysiological mechanisms of these drugs, we suggest combining sensitive and specific behavioral tools with neuroimaging and electrophysiological measures in large randomized, double-blind, placebo-controlled experimental designs. We conclude that the pharmacokinetics and pharmacodynamics of amantadine, apomorphine and zolpidem need further exploration to determine which treatment would provide a better neurological outcome regarding the patient’s etiology, diagnosis, time since injury and overall condition.
Export Options
About this article
Cite this article as:
Gosseries Olivia, Charland-Verville Vanessa, Thonnard Marie, Bodart Olivier, Laureys Steven and Demertzi Athena, Amantadine, Apomorphine and Zolpidem in the Treatment of Disorders of Consciousness, Current Pharmaceutical Design 2014; 20 (26) . https://dx.doi.org/10.2174/13816128113196660654
DOI https://dx.doi.org/10.2174/13816128113196660654 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Protein Conformational Dynamics and DNA Integrity in Relevance to Neuronal Cell Death in Neurodegeneration
Current Alzheimer Research Anti-Neuroinflammatory Potential of Polyphenols by Inhibiting NF-κB to Halt Alzheimer's Disease
Current Pharmaceutical Design Neuropharmacological Mechanisms Underlying the Neuroprotective Effects of Methylphenidate
Current Neuropharmacology Adipose Tissue Derived Stem Cells Secretome: Soluble Factors and Their Roles in Regenerative Medicine
Current Stem Cell Research & Therapy West Nile Virus Vaccine.
Current Drug Targets - Infectious Disorders A Co-Module Regulated by Therapeutic Drugs in a Molecular Subnetwork of Alzheimer’s Disease Identified on the Basis of Traditional Chinese Medicine and SAMP8 Mice
Current Alzheimer Research Nanoparticle Mediated Gene Therapy: A Trailblazer Armament to Fight CNS Disorders
Current Medicinal Chemistry Genomic Linkage Between Alzheimer's Disease and Type 2 Diabetes
CNS & Neurological Disorders - Drug Targets Biomedical Perspectives of Acute and Chronic Neurological and Neuropsychiatric Sequelae of COVID-19
Current Neuropharmacology Editorial [Hot topic: New Therapeutic Strategies for Treatment of Neurodegenerative Diseases (Executive Editor: Aleksey G. Kazantsev)]
Current Pharmaceutical Design Neurosteroids in the Brain Neuron: Biosynthesis, Action and Medicinal Impact on Neurodegenerative Disease
Central Nervous System Agents in Medicinal Chemistry Reperfusion Therapies for Acute Ischemic Stroke: An Update
Current Cardiology Reviews Antifungal Therapy Used in Central Nervous System Fungal Infections
Central Nervous System Agents in Medicinal Chemistry Quantitative Imaging Biomarkers and their Emerging Role
Current Medical Imaging Current Overview on the Usage of Poly(ADP-ribose)polymerase (PARP) Inhibitors in Treating Cancer
Clinical Cancer Drugs Organotypic Cultures as Tools for Testing Neuroactive Drugs – Link Between In-Vitro and In-Vivo Experiments
Current Medicinal Chemistry Neuroprotective Properties of Erythropoietin in Cerebral Ischemia
Central Nervous System Agents in Medicinal Chemistry Combining Anti-tumor Alkyl-Phospholipid Analogs and Radiotherapy: Rationale and Clinical Outlook
Anti-Cancer Agents in Medicinal Chemistry Cannabinoids and Myocardial Ischemia: Novel insights, Updated Mechanisms, and Implications for Myocardial Infarction
Current Medicinal Chemistry Targeting CSC-Related miRNAs for Cancer Therapy by Natural Agents
Current Drug Targets